Dr. Jonathan E. Markowitz, M.D.
Pediatric Gastroenterology (Pediatric Gastroenterology Physician)
200 Patewood Dr, Suite A140
Greenville, SC 29615
Who else practices at this address →
Greenville County is a federal mental health shortage area. About shortage areas
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Gastroenterology Physician primary
SC license 28498
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 10 companies reported 29 payments worth $4,088 in total to this clinician.
| Genzyme Corporation | $3,582 |
|---|---|
| Qol Medical, LLC | $160 |
| Janssen Biotech, Inc. | $86.39 |
| Ipsen Biopharmaceuticals, Inc | $78.78 |
| Takeda Pharmaceuticals U.S.A., Inc. | $47.27 |
| Mirum Pharmaceuticals, Inc. | $39.38 |
| Alcresta Therapeutics, Inc. | $33.51 |
| Regeneron Healthcare Solutions, Inc. | $28.14 |
| Consulting Fee | $3,512 |
|---|---|
| Food and Beverage | $576 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Apr 23, 2025 | Consulting Fee | $1,756 |
| Genzyme Corporation Jun 17, 2025 | Consulting Fee | $1,756 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $62,268 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis.
Celgene Corporation - 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
Ardelyx, Inc. · Completed · NCT06553547 - An open-label long-term safety study of tenapanor for the treatment of irritable bowel syndrome with constipation (ibs-c) in pediatric patients 6 to less than 18 years old
Ardelyx, Inc. - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis.
E.r. Squibb & Sons, L.l.c. - Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
Ardelyx, Inc. · Completed · NCT05643534 - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosino…
Celgene Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.